Alkermes Completes Enrollment for Registration Study of VIVITROL[R] in Patients with Opioid Dependence.
Business Wire › April 21, 2009
Linked as:
Extract
Alkermes Completes Enrollment for Registration Study of VIVITROL[R] in Patients with Opioid Dependence.
- VIVITROL Clinical Development Program Expanded with Phase 3b Study in Healthcare Professionals -
CAMBRIDGE, Mass. -- Alkermes, Inc. (NASDAQ: ALKS) today announced that it has completed patient enrollment for the registration study of VIVITROL([R])(naltrexone for extended-release injectable suspension) for the treatment of opioid dependence, a chronic brain disease. The data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA...See the full content of this document
Sponsored links
